ERIUS 5MG PILLS
ERIUS 5MG PILLS - 5 tablets
Security policy (edit with Customer reassurance module)
Delivery policy (edit with Customer reassurance module)
Return policy (edit with Customer reassurance module)
Trade name of the drug - Erius®
International non-proprietary name - Desloratadine
Dosage Form - film-coated tablets
Active substance: desloratadine 5 mg.
Excipients: Calcium hydrophosphate dihydrate 53 mg, cellulose
microcrystalline 28 mg, corn starch 11 mg, talc 3 mg.
Tablet shell: opadry blue (lactose monohydrate, hypromellose, titanium
dioxide, macrogol, aluminum blue varnish) 6 mg, opadry transparent (hypromellose,
macrogol) 0.6 mg, carnauba wax 0.005 mg, beeswax white 0.005 mg.
Round biconvex pills of blue color. On the one hand pill method
The stamping of the Schering-Plow trademark in the form of stylized letters SP.
Antiallergic - H1-histamine receptor blocker.
Antihistamine drug long-acting. Is the primary active
metabolite of loratadine. Inhibits a cascade of allergic inflammation reactions, including
including the release of pro-inflammatory cytokines, including IL-4 interleukins,
IL-6, IL-8, IL-13, release of proinflammatory chemokines (RANTES),
production of superoxide anions by activated polymorphonuclear
neutrophils, adhesion and eosinophil chemotaxis, the release of adhesion molecules such as
P-selectin, IgE-mediated release of histamine, prostaglandin D2 and
leukotriene C4. Thus, it prevents the development and facilitates the course of allergic reactions, has antipruritic and anti-exudative action,
reduces capillary permeability, prevents the development of tissue edema, spasm
The drug has no effect on the central nervous system, almost no
has a sedative effect (does not cause drowsiness) and does not affect the speed
psychomotor reactions. Does not cause lengthening of the QT interval on the ECG.
The effect of the drug Erius® begins within 30 minutes after taking
inside and lasts for 24 hours.
Desloratadine is well absorbed in the gastrointestinal tract. Determined in plasma
blood 30 minutes after ingestion. The maximum concentration is reached in
on average 3 hours after ingestion. Does not penetrate the blood-brain barrier.
Communication with plasma proteins is 83-87%. When used in adults and adolescents in
for 14 days at a dose of 5 mg to 20 mg 1 time per day of clinically significant cumulation
drug is not marked. Simultaneous ingestion of food or grapefruit juice is not
affects the distribution of desloratadine when used at a dose of 7.5 mg 1 time per day.
Desloratadine is not a CYP3A4 and CYP2D6 inhibitor and is not a substrate or
an inhibitor of P-glycoprotein.Intensively metabolized in the liver by
hydroxylation to form 3-OH-desloratadine, coupled with a glucuronide.
Only a small part of the ingested dose is eliminated by the kidneys (<2%) and after
intestine (<7%). The half-life is 20-30 hours (on average, 27 hours).
Indications for use
- allergic rhinitis (elimination or relief of sneezing, nasal congestion,
discharge of mucus from the nose, itching of the nose, itching of the palate, itching and redness of the eyes, watery eyes);
- hives (reduction or elimination of pruritus, rash).
- hypersensitivity to any of the substances that make up the drug,
- pregnancy and lactation,
- age up to 12 years.
- severe renal failure.
Application ____________ during pregnancy and lactation
The use of the drug during pregnancy is contraindicated due to the lack
clinical data on the safety of the drug Erius® in
Desloratadine, the active substance, is excreted in breast milk; therefore,
Erius® drug during breastfeeding is contraindicated.
Dosage and administration
For oral administration. The pill should be swallowed whole, not chewed, and drink
water The drug is preferably taken regularly at the same time of day, regardless
from the time of eating.
Adults and teenagers from 12 years - on 1 pill (5 mg) once a day.
Symptoms Receiving a dose exceeding the recommended 5 times, did not lead to
the appearance of any symptoms. During clinical trials daily
use in adults and adolescents desloratadine in a dose of up to 20 mg for 14 days not
accompanied by statistically or clinically significant changes from
of cardio-vascular system. In the clinical and pharmacological study the use of
desloratadine at a dose of 45 mg per day (9 times higher than recommended) for 10 days is not
caused a prolongation of the QT interval and was not accompanied by the appearance of serious side effects.
Treatment. In case of accidental ingestion of large quantities of the drug must
Seek immediate medical attention. Recommended gastric lavage, taking
activated carbon; if necessary, symptomatic therapy. Desloratadine not
displayed during hemodialysis, the effectiveness of peritoneal dialysis has not been established.
Fatigue (1.2% of cases), dry mouth (0.8%), headache
The following side effects were very rare: tachycardia, palpitations,
increased activity of liver enzymes, increasing the concentration of bilirubin,
allergic reactions, including anaphylaxis and rashes.
Interaction with other drugs
Interaction with other drugs was not detected. Meal not
affects the effectiveness of the drug. Erius® does not enhance the effect of alcohol
on the central nervous system.
Research on the effectiveness of the drug Erius® in rhinitis infectious
etiology was not carried out.
Influence on ability to drive motor transport and control mechanisms
At the recommended dose, Erius® does not affect the ability to drive motor vehicles.
funds or management mechanisms.
Tablets, film coated, 5 mg. 1, 2, 3, 5, 7 or 10 pills in a blister
PVC and aluminum foil. Through 1, 2, 3, 5, 9 or 10 blisters along with instructions for
application in a carton box.
At a temperature not higher than 30 ° C, out of the reach of children.
2 years. Do not use after expiration date.
Over the counter.